Abstract
Pharmaceutical Patent AnalystVol. 6, No. 3 CommentaryAre therapeutic antibodies still patentable at the European Patent Office?Vicki Allen & Graham Matthew LewisVicki Allen J A Kemp, 14 Gray’s Inn, South Square, London, WC1R 5JJ, UKSearch for more papers by this author & Graham Matthew Lewis*Author for correspondence: E-mail Address: glewis@jakemp.com J A Kemp, 14 Gray’s Inn, South Square, London, WC1R 5JJ, UKSearch for more papers by this authorPublished Online:9 May 2017https://doi.org/10.4155/ppa-2017-0008AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: antibodiesEuropean Patent Officeinventive stepReferences1 Reichert JM. Antibodies to watch in 2017. mAbs 9(2), 167–181 (2017).Crossref, Medline, CAS, Google Scholar2 Enlarged Board of Appeal Decision G2/08. www.epo.org/law-practice/case-law-appeals/pdf/g080002ex1.pdfGoogle Scholar3 Technical Board of Appeal Decision T735/00. www.epo.org/law-practice/case-law-appeals/pdf/t000735eu1.pdfGoogle Scholar4 Technical Board of Appeal Decision T0067/11. www.epo.org/law-practice/case-law-appeals/pdf/t110067eu1.pdfGoogle Scholar5 Technical Board of Appeal Decision T1329/04. www.epo.org/law-practice/case-law-appeals/pdf/t041329eu1.pdfGoogle Scholar6 Technical Board of Appeal Decision T2637/11. www.epo.org/law-practice/case-law-appeals/pdf/t112637eu1.pdfGoogle ScholarFiguresReferencesRelatedDetails Vol. 6, No. 3 Follow us on social media for the latest updates Metrics Downloaded 62 times History Published online 9 May 2017 Published in print May 2017 Information© Future Science LtdKeywordsantibodiesEuropean Patent Officeinventive stepFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
